Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 238,343,922 papers from all fields of science
Search
Sign In
Create Free Account
exemestane
Known as:
Exemestano
, exemestane [Chemical/Ingredient]
, examestane
Expand
A drug used to treat advanced breast cancer and to prevent recurrent breast cancer in postmenopausal women who have already been treated with…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
12 relations
Broader (3)
Androstadienes
Antineoplastic Agents
Aromatase Inhibitors
Narrower (3)
Aromasin
FCE 24304
PNU 155971
Drug Allergy
Mammary Neoplasms
NCIt Antineoplastic Agent Terminology
Pregnancy
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Abstract P4-22-20: Efficacy and safety of everolimus plus exemestane in HR+, HER2– advanced breast cancer progressing on/after prior endocrine therapy, in routine clinical practice: 2ndinterim…
G. Steger
,
R. Bartsch
,
+13 authors
M. Gnant
2017
Corpus ID: 79211524
Background STEPAUT, an Austrian non-interventional study evaluated the safety and efficacy of everolimus (EVE) + exemestane (EXE…
Expand
2014
2014
A Validated Stability-Indicating Liquid Chromatographic Method for the Determination of Exemestane
M. M. Annapurna
,
B. Swati
,
D. Ramya
,
K. Pramadvara
,
A. Ram
,
N. Aslesha
2014
Corpus ID: 55585833
A stability indicating liquid chromatographic method was developed for the determination of Exemestane in presence of degradation…
Expand
2012
2012
Use of endocrine therapy following diagnosis of ductal carcinoma in situ or early invasive breast cancer
B. Virnig
,
M. Torchia
,
Stephanie L. Jarosek
,
Sara B. Durham
,
T. Tuttle
2012
Corpus ID: 68396035
2012
2012
Can FDG PET/CT monitor the response to hormonal therapy in breast cancer patients?
L. Evangelista
,
D. Rubello
,
G. Saladini
European Journal of Nuclear Medicine and…
2012
Corpus ID: 12370111
As breast cancer becomes metastatic, it becomes incurable and the goals of treatment are palliation of symptoms, prolongation of…
Expand
2011
2011
Exemestane for primary prevention of breast cancer in postmenopausal women: NCIC CTG MAP.3-A randomized, placebo-controlled clinical trial.
Paul E. Goss
,
J. Ingle
,
+17 authors
Harriet Richardson
Journal of Clinical Oncology
2011
Corpus ID: 28176879
LBA504 Background: Limited efficacy and serious toxicities have limited uptake of tamoxifen or raloxifene as preventatives of…
Expand
2004
2004
A comparative study of exemestane versus anastrozole in post-menopausal breast cancer subjects with visceral disease.
D. Cameron
,
E. Winer
,
S. Campos
,
J. Guastalla
Journal of Clinical Oncology
2004
Corpus ID: 199593455
628 Background: A pilot, open-label, multicenter, multinational, randomized, parallel group, comparative study was conducted in…
Expand
2004
2004
The excretion study of exemestane in man
Navaporn Saardpun
,
Sutheema Nimsongnern
,
+5 authors
T. Anukarahanonta
2004
Corpus ID: 111998547
Proceedings of the Manfred Donike Workshop, 22 nd Cologne Workshop on Dope Analysis 7-12 March 2004
Review
2001
Review
2001
Role of anti-aromatase agents in postmenopausal advanced breast cancer
R. Murray
Cancer Chemotherapy and Pharmacology
2001
Corpus ID: 34707699
Abstract.Purpose: Endocrine therapy is a well-recognized approach to the treatment of postmenopausal patients with advanced…
Expand
2000
2000
Exemestane (Aromasin) is active and well tolerated as first-line hormonal therapy (HT) of metastatic breast cancer (MBC) patients (pts): results of a randomized phase II trial
R. Paridaens
,
L. Dirix
,
+8 authors
M. Piccart
2000
Corpus ID: 78401383
2000
2000
Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol
A. Messori
,
F. Cattel
,
S. Trippoli
,
M. Vaiani
Anti-Cancer Drugs
2000
Corpus ID: 44563316
In patients with metastatic breast cancer, second-line therapy with aromatase inhibitors can improve survival in comparison with…
Expand